
Prof David Bates
Professor of Oncology
University of Nottingham Centre for Cancer Sciences and University of Pretoria Pan African Cancer Research Institute
Integrated physiology as a route for development of new treatments for blindness and cardiovascular disease – a tail of VEGFs!
View biography
Professor David Bates is Professor of Oncology at the University of Nottingham Centre for Cancer Sciences, and Professor Extraordinaire at the University of Pretoria Pan African Cancer Research Institute. He is the founder of three spin-out companies. Exonate Ltd has developed an eye drop for treatment of diabetic retinopathy. IsomAb Ltd is developing VEGF isoform-specific antibodies for the treatment of cardiovascular diseases, and Emenda Therapeutics is developing splicing factor kinase inhibitors for arthritis, pain and other conditions. His academic research investigates regulation of alternative splicing and anti-angiogenic and immune approaches to cancer. He has discovered how angiogenic factors contribute to cancer, age-related macular degeneration, diabetic retinopathy, nephropathy and neuropathy, lung and heart disease and other conditions, and identified splicing factor kinases as key regulators of cancer and other diseases. At Nottingham he led the development, funding and establishment of the University of Nottingham Centre for Cancer Sciences, bringing together cancer academic groups from epidemiology to molecular genetics. His collaborations include cholangiocarcinoma research in Thailand and Laos and colorectal and other cancers at the University of Pretoria. He has served on a South African MRC Scientific Advisory Board and held leadership roles at the University of Nottingham. He has also been a Non-Executive Director of Nottingham University Hospitals NHS Trust and is a backcountry ski guide for the Austrian Alpine Club.









